NASH Companies Take The Stage At AASLD

Without an approved therapy to establish a treatment paradigm, the non-alcoholic steatohepatitis (NASH) market is still untested – leaving the cluttered research and development space with a mix of companies testing different pathways and theories for treating the unmet medical need. At the American Association for the Study of Liver Diseases annual meeting in Boston 8-12 November, Scrip spoke to several companies with mid-stage programs about their aspirations in the crowded field.

Those companies include NGM Biopharmaceuticals Inc., which has the FGF19 analogue aldafermin (NGM282) in Phase IIb for NASH;